source
- Chiesi to acquire KalVista for $1.9 billion, adding hereditary angioedema pill to rare-disease portfolioItalian pharmaceutical group Chiesi announced it will purchase KalVista Therapeutics for $1.9 billion. The transaction values KalVista at $27 per share, a 40 percent premium to its last closing pri…
- Supreme Court hints skinny labeling may remain viable for generic drugsAt a hearing, Supreme Court justices heard arguments about skinny labeling, a practice used by generic manufacturers to seek approval for a subset of a brand drug's indications. The justices did n…